HIV infection currently has no effective cures and requires lifelong antiretroviral treatments. Cures have failed due to HIVs immune evasion and rapid mutation rate. Here we present a first in class HIV therapeutic vaccine, termed nanotrap therapeutic vaccines (NTVs) that are designed to capture circulating HIV virions and facilitate internalization by local antigen presenting cells. NTVs are modified liposomes that display the CD4 mimetic molecule, CJF-III-288, on their surfaces and have the TL